Mitogenic signaling by the gep oncogene involves the upregulation of S-phase kinase-associated protein 2

Genes and Cancer

Volumn 1, Issue 10, 2010, Pages 1033-1043

  Radhakrishnan, Rangasudhagar ^a,b   Ha, Ji Hee ^a   Dhanasekaran, Danny N ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

G12; JNK; LPA; Oncogene; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; G PROTEIN G12; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; S PHASE KINASE ASSOCIATED PROTEIN 2; STRESS ACTIVATED PROTEIN KINASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTROCYTOMA; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST CULTURE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOGENESIS; NONHUMAN; ONCOGENE; ONCOGENE GEP; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79952821268     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910390516     Document Type: Article

References (61)

1. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005;27:1329-39.
2. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79-94.
3. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857-65.
4. Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009;8:3695-701.
5. Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 2007;120:921-8.
6. Mazzuco TL, Chabre O, Feige JJ, Thomas M. Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis. Mol Cell Endocrinol. 2007;265-266:23-8.
7. Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002;107:259-83.
8. Aly A, Shulkes A, Baldwin GS. Gαstrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta. 2004;1704:1-10.
9. Yowell CW, Daaka Y. G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer. 2002;1:177-81.
10. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther. 2004;3:1031-9.
11. Juneja J, Casey PJ. Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol. 2009;158:32-40.
12. Radhika V, Dhanasekaran N. Transforming G proteins. Oncogene. 2001;20:1607-14.
13. 13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo. Clin Cancer Res. 2010;16:1402-15.
14. 13. J Biol Chem. 1995;270:18655-9.
15. 13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells. J Biol Chem. 1996;271:21081-7.
16. 12 stimulates c-Jun NH2 -terminal kinase through the small G proteins Ras and Rac. J Biol Chem. 1996;271:17349-53.
17. 12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature. 1998;395:808-13.
18. 12 stimulates cell proliferation through cycloxygenase-2 signaling pathway. Oncogene. 1999;18:7185-9.
19. 12. Oncogene. 2004;23:226-32.
20. 12, involves signaling by STAT3. Oncogene. 2006;25:899-906.
21. 12. Mol Cell Biol. 2006;26:50-62.
22. Aragay AM, Collins LR, Post GR, et al. G12 requirement for thrombinstimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells. J Biol Chem. 1995;270:20073-7.
23. 12: regulation of leukemia-associated protein SET. J Proteome Res. 2004;3:1177-83.
24. 12-induced G1 to S phase cell cycle progression on both Ras/ mitogen-activated protein kinase and Ras/Rac1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts. J Biol Chem. 1997;272:4904-10.
25. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79: 551-5.
26. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995; 11:211-9.
27. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-66.
28. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-69.
29. Grana X, Gαrriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene. 1998;17:3365-83.
30. Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta. 2001;1471:M123-33.
31. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol. 1999;9:661-4.
32. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-9.
33. Pegano M. Control of DNA synthesis and mitosis by the Skp2-p27- Cdk1/2 axis. Mol Cell. 2004;14:414-6.
34. Nakayama K-I, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Bioche Biophys Res Commun. 2001;282:853-60.
35. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010;102:941-6.
36. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta. 2002;1582:265-9.
37. Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595-605.
38. Kishi Y, Okudaira S, Tanaka M, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidy-lcholine to lysophosphatidic acid. J Biol Chem. 2006;281:17492-500.
39. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001;98:2515-20.
40. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001;98: 5043-8.
41. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008;112:1415-24.
42. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633-41.
43. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002;8:3419-26.
44. Einama T, Kagata Y, Tsuda H, et al. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas. 2006;32:376-81.
45. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res. 2003;9:1756-63.
46. Saigusa K, Hashimoto N, Tsuda H, et al. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 2005;96:676-83.
47. Schiffer D, Cavalla P, Fiano V, Ghimenti C, Piva R. Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett. 2002;328:125-8.
48. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001;61:7044-7.
49. Modiano JF, Domenico J, Szepesi A, Lucas JJ, Gelfand EW. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J Biol Chem. 1994;269:32972-8.
50. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8:287-301.
51. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272:12738-46.
52. Gαo N, Flynn DC, Zhang Z, et al. G cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281-91.
53. Gilchrist A, Vanhauwe JF, Li A, Thomas TO, Voyno-Yasenetskaya T, Hamm HE. Gα minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin mediated endothelial activation. J Biol Chem. 2001;276:25672-9.
54. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23:1534-45.
55. Villanueva J, Yung Y, Walker JL, Assoian RK. ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell. 2007;18:1457-63.
56. Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/ PKB. Nat Cell Biol. 2009;11:420-32.
57. Bryant P, Zheng Q, Pumiglia K. Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and-independent mechanisms. Mol Cell Biol. 2006;26:4201-13.
58. 12. Oncogene. 2005;24:4597-603.
59. Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene. 2007;26:3122-42.
60. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1:53-62.
61. 12. J Biol Chem. 1997;272:28829-32.